Suppr超能文献

肺多形性、梭形细胞和巨细胞癌中PD-L1的表达与TTF-1、p40表达相关,可能提示预后较差。

PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.

作者信息

Yvorel Violaine, Patoir Arnaud, Casteillo François, Tissot Claire, Fournel Pierre, Stachowicz Marie-Laure, Karpathiou Georgia, Tiffet Olivier, Péoc'h Michel, Forest Fabien

机构信息

Department of Pathology, North Hospital, University Hospital of Saint Etienne, Saint Etienne, France.

Department of Thoracic Surgery, North Hospital, University Hospital of Saint Etienne, Saint Etienne, France.

出版信息

PLoS One. 2017 Jul 3;12(7):e0180346. doi: 10.1371/journal.pone.0180346. eCollection 2017.

Abstract

Lung sarcomatoid carcinoma of the lung is a rare tumor with a poor prognosis. More than 90% of them are pleomorphic, spindle cell and giant cell carcinoma (PSCGCC). This rare subtype of lung cancer is thought to be more resistant to chemotherapy, and a small subset of them seems to exhibit targetable mutations. Immunotherapy against PD1/PDL-1 is a new emerging treatment, and might be of interest in PSGSCC because they frequently express PD-L1. The aim of our work is to evaluate PD1 and PDL-1 expression in a surgical series of lung PSCGCC and their relationship with morphological and immunohistochemical parameters and prognosis. Thirty-six patients who underwent surgical resection of a PSGSCC were included. PD-L1 (E1L3N) expression on tumor cells and PD1 (NAT105) expression by tumor infiltrating lymphocytes (TILs) were performed by immunohistochemistry. Results were compared to immunohistochemistry tests of TTF1, Napsin A, p40 and to molecular study of EGFR, KRAS, BRAF and HER2. Seventy-five % of PSCGCC were considered as positive for PD-L1.PD-L1 expression in PSGSCC is associated with TTF-1 and/or Napsin A expression (47.2%, p = 0.039). Few p40 positive PSCGCC expressed PD-L1 (8.3%, p = 0.013). PD1 expression was not related to TTF-1 and/or Napsin A expression (p = 0.47), p40 expression (p = 0.68) or survival (p = 0.14). PD-L1 or PD1 expression were not related to the age, gender, pT, pN, stage, visceral pleura invasion, histopathological subtype, the presence of giant cell component, the predominance of sarcomatoid component, and the presence of EGFR or BRAF or HER2 or PIK3CA mutation (p>0.05). PD-L1 expression was correlated with a worse overall survival in PSCGCC (p = 0.045). PD-L1 expression is frequent in PSCGCC and might be associated with the expression of adenocarcinoma markers (TTF-1, Napsin A) or the lack of expression of squamous cell carcinoma marker (p40).

摘要

肺肉瘤样癌是一种预后较差的罕见肿瘤。其中超过90%为多形性、梭形细胞和巨细胞癌(PSCGCC)。这种罕见的肺癌亚型被认为对化疗更具抗性,并且其中一小部分似乎存在可靶向的突变。针对PD1/PDL-1的免疫疗法是一种新兴的治疗方法,在PSGSCC中可能具有应用价值,因为它们经常表达PD-L1。我们研究的目的是评估手术切除的肺PSCGCC中PD1和PD-L1的表达情况,以及它们与形态学、免疫组化参数和预后的关系。纳入了36例行PSGSCC手术切除的患者。通过免疫组化检测肿瘤细胞上的PD-L1(E1L3N)表达以及肿瘤浸润淋巴细胞(TILs)上的PD1(NAT105)表达。将结果与TTF1、Napsin A、p40的免疫组化检测以及EGFR、KRAS、BRAF和HER2的分子研究结果进行比较。75%的PSCGCC被认为PD-L1呈阳性。PSGSCC中PD-L1表达与TTF-1和/或Napsin A表达相关(47.2%,p = 0.039)。少数p40阳性的PSCGCC表达PD-L1(8.3%,p = 0.013)。PD1表达与TTF-1和/或Napsin A表达(p = 0.47)、p40表达(p = 0.68)或生存率(p = 0.14)无关。PD-L1或PD1表达与年龄、性别、pT、pN、分期、脏层胸膜侵犯、组织病理学亚型、巨细胞成分的存在、肉瘤样成分的优势以及EGFR或BRAF或HER2或PIK3CA突变的存在均无关(p>0.05)。PD-L1表达与PSCGCC中较差的总生存率相关(p = 0.045)。PD-L1表达在PSCGCC中很常见,并且可能与腺癌标志物(TTF-1、Napsin A)的表达或鳞状细胞癌标志物(p40)的缺乏表达有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee97/5495439/099921bb3505/pone.0180346.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验